UCB (EBR:UCB) UCB Media Room: Share Repurchase Program 2021

Transparency directive : regulatory news

05/03/2021 20:08

https://mb.cision.com/Public/18595/3301187/a2c6b78674ae205f_800x800ar.jpg ** Share Repurchase Program 2021 to cover UCB's Long Term Incentive Plans f= or its employees ------------------------------------------------------------ Brussels (Belgium), 5 March 2021 =E2=80=93 20:05 (CET) =E2=80=93 regulated = information In application of article 7:215 of the Belgian Code of Companies and Associ= ations, UCB SA/NV (=E2=80=9CUCB=E2=80=9D or the =E2=80=9CCompany) (Euronext= Brussels: UCB) announces the launch of a share buy-back program (the =E2= =80=9CShare Repurchase Program 2021=E2=80=9D), effective as of 8 March 2021= .=C2=A0 The repurchase of UCB shares under this program intends to cover current an= d future obligations under UCB's Long Term Incentive Plans for its employee= s. UCB will continuously monitor both its current and future obligations un= der such plans in view of keeping an adequate level of treasury shares. Under this program, UCB may acquire from time to time its common stock, for= a maximum of 750 000 shares. The share repurchases will be conducted under= the terms and conditions approved by the extraordinary general shareholder= s=E2=80=99 meeting of the Company held on 30 April 2020. The timing of the = repurchase of shares pursuant to the program will depend on a variety of fa= ctors, including market conditions. The program may be suspended or discont= inued at any time. UCB has requested a financial intermediary to repurchase UCB shares on its = behalf under the terms of an initial discretionary mandate agreement with v= alidity until 25 June 2021.=C2=A0 During the Share Repurchase Program 2021, regular updates will be published= in accordance with applicable legislation. This press release is available on UCB SA/NV=E2=80=99s website via the foll= owing link (https://www.ucb.com/stories-media/Press-Releases) . Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, =C2=A0Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With approximately 8 400 peopl= e in approximately 40 countries, the company generated revenue of =E2=82=AC= 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Fol= low us on Twitter: @UCB_news GenericFile 20210305 - UCB Programme de rachat d actions propres 2021 FR (https://mb.ci= sion.com/Public/18595/3301187/a8bb17dbe848a272.pdf) GenericFile 20210305 UCB Share Repurchase Program 2021 ENG (https://mb.cision.com/Publi= c/18595/3301187/b592b9b71ecbc643.pdf) GenericFile 20210305 UCB Aandelen Inkoop Programma 2021 NED (https://mb.cision.com/Publ= ic/18595/3301187/b31b6497ca7efd24.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x63194x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

UCB's latest news

25/04/2024 18:00

UCB (EBR:UCB) UCB Media Room: Share Repurchase Program 2021

Transparency directive : regulatory news

UCB's latest news

Other stories